IP Library Patent Application 12815704
Patent Application
App. No. 12/815,704

PROCESS FOR THE MANUFACTURE OF VALSARTAN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/815,704
Abstract

The present invention relates to a process for the manufacture of an angiotensin receptor blocker (ARB; also called angiotension II receptor antagonist or AT 1 receptor antagonist) and salts thereof, to novel intermediates and process steps.

Claims (34)

1 . A process for the manufacture of the compound of formula (I)

or a salt thereof, comprising

(a) reacting a compound of formula (II a)

or a salt thereof, wherein R 1 is hydrogen or a tetrazole protecting group, with a compound of formula

or a salt thereof, wherein R 2 represents hydrogen or a carboxy protecting group, under the conditions of a reductive amination; and

(b) acylating a resulting compound of formula (II c)

or a salt thereof with a compound of formula (II d)

wherein R 3 is an activating group; and,

(c) if R 1 and/or R 2 are different form hydrogen, removing the protecting group(s) in a resulting compound of formula (II e)

or a salt thereof; and

(d) isolating a resulting compound of formula (I) or a salt thereof; and, if desired, converting a resulting free acid of formula (I) into a salt thereof or converting a resulting salt of a compound of formula (I) into the free acid of formula (I) or converting a resulting salt of a compound of formula (I) into a different salt.

2 . The process according to claim 1 , wherein in compounds of formulae (II a), (II b), (II c), and (II e) R 1 represents hydrogen and R 2 represents hydrogen and wherein in compounds of formula (II d) R 3 represents halogen.

3 . The process according to claim 1 , wherein the reductive amination is carried out in the presence of a reducing agent such as a borohydride, which may also be in complexed form, or hydrogen or a hydrogen donor both in the presence of a hydrogenation catalyst.

4 . The process according to claim 1 , wherein step (a) is carried out by first forming an imine of formula

by condensing compounds of formulae (II a) and (II b) and by removing water and then followed by reducing a compound of formula (IIc′) in the presence of a reducing agent.

5 . The process according to claim 1 , wherein step (b) is carried out by first adding a compound of formula (II d) to a compound of formula (II c) and then slowly adding a sub-stoichiometric amount of a base in relation to the compound of formula (II d).

6 . A process for the manufacture of a compound of formula

wherein R 1 represents hydrogen or a tetrazole protecting group and R 2 represents hydrogen or a carboxy protecting group,

comprising reacting a compound of formula (II a)

or a salt thereof, wherein R 1 is hydrogen or a tetrazole protecting group, with a compound of formula

or a salt thereof, wherein R 2 represents hydrogen or a carboxy protecting group, under the conditions of a reductive amination.

7 . A process according to claim 6 , comprising reacting a compound of formula (II a)

or a salt thereof, wherein R 1 is hydrogen or a tetrazole protecting group, with a compound of formula

or a salt thereof, wherein R 2 represents hydrogen or a carboxy protecting group, while eliminating water, and reducing a resulting compound of formula (II c′)

in the presence of a reducing agent.

8 . A compound of formula

wherein R 1 is hydrogen or a tetrazole protecting group and R 2 is hydrogen or a carboxy protecting group, excluding a compound of formula (II c) wherein R 1 is ethyl and R 2 is trityl.

9 . A compound of formula

wherein R 1 is hydrogen or a tetrazole protecting group and R 2 is hydrogen or a carboxy protecting group.

10 . A process for the manufacture of a compound of formula

wherein R 1 represents hydrogen or a tetrazole protecting group and R 2 represents hydrogen or a carboxy protecting group,

comprising acylating a resulting compound of formula (II c)

or a salt thereof with a compound of formula (II d)

wherein R 3 is an activating group.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2011
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 026002/0790 →